Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM).
Ann Oncol
; 33(12): 1328-1331, 2022 12.
Article
in En
| MEDLINE
| ID: mdl-36122799
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Precision Medicine
/
Neoplasms
Type of study:
Diagnostic_studies
/
Prognostic_studies
Limits:
Humans
Language:
En
Journal:
Ann Oncol
Year:
2022
Document type:
Article